A5016711138- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Eosinophilic Disorders and Syndromes
- Mast cells and histamine
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Click Chemistry and Applications
- Protein Degradation and Inhibitors
- Urticaria and Related Conditions
- Multiple Myeloma Research and Treatments
- Asthma and respiratory diseases
- Histone Deacetylase Inhibitors Research
- CAR-T cell therapy research
- Retinoids in leukemia and cellular processes
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Eosinophilic Esophagitis
- Cancer therapeutics and mechanisms
- Lymphoma Diagnosis and Treatment
- Microtubule and mitosis dynamics
- Neutropenia and Cancer Infections
- DNA Repair Mechanisms
- Epigenetics and DNA Methylation
- Hematopoietic Stem Cell Transplantation
- Monoclonal and Polyclonal Antibodies Research
Azienda Unità Sanitaria Locale Della Romagna
2016-2025
Ospedale "Santa Maria delle Croci" di Ravenna
2007-2025
University of Bologna
2002-2024
Ospedale Santa Maria
2019-2024
Ospedale Infermi di Rimini
2022
Medical University of Vienna
2022
Azienda-Unita' Sanitaria Locale Di Cesena
2014-2018
University of Siena
2008-2015
Ospedale Santa Maria alle Scotte
2010
Istituto di Ematologia di Bologna
2008
Background and Objectives The hypereosinophilic syndrome (HES) may be associated with the fusion of platelet derived growth factor receptor α (PDGFRα) gene FIP1L1 in chromosome 4 coding for a constitutively activated PDGFRα tyrosine kinase. These cases FIP1L1-PDGFRα rearrangement have been reported to very sensitive kinase inhibitor imatinib mesylate.Design Methods A prospective multicenter study idiopathic or primary HES was established 2001 (Study Protocol Registration no. NCT 0027 6929)....
The emergence of resistance to the Bcr-Abl inhibitor imatinib mesylate in patients with Philadelphia chromosome-positive (Ph+) leukemia has prompted development second-generation compounds active against several imatinib-insensitive mutant forms Bcr-Abl, including dasatinib (BMS-354825; Bristol-Myers Squibb). In order assess which pre-existent or emerging kinase domain mutations are associated decreased clinical efficacy desatinib, we analyzed BCR-ABL sequences before and during treatment 21...
Therapy-related myeloid neoplasms (t-MN) are a complication of cytotoxic treatment for primary tumors and autoimmune diseases. We report data on 277 t-MN patients, recruited between 1999 2013 by the Italian Network Secondary Leukemias (104 retrospectively 173 prospectively registered). Median age at diagnosis was 64 years (range, 21-87). Most frequent malignancies (PMs) were lymphoproliferative diseases breast cancer. One hundred thirty-three patients had received chemotherapy (CHT), 43...
Systemic mastocytosis is a rare heterogeneous myeloproliferative neoplasm characterized by abnormal proliferation and activation of mast cells. We describe large multicentre series 460 adult patients with systemic mastocytosis, diagnosis based on WHO 2008 criteria, in “real‐life” setting ten Italian centers dedicated multidisciplinary programs. included indolent forms ( n = 255) without 165) skin lesions, smouldering 20), aggressive 28), associated other hematological diseases 21) cell...
Secondary acute myeloid leukemia (sAML) poorly responds to conventional treatments and allogeneic stem cell transplantation (HSCT). We evaluated toxicity efficacy of CPX-351 in 71 elderly patients (median age 66 years) with sAML enrolled the Italian Named (Compassionate) Use Program. Sixty days treatment-related mortality was 7% (5/71). The response rate at end treatment was: CR/CRi 50/71 (70.4%), PR 6/71 (8.5%), NR 10/71 (19.7%). After a median follow-up 11 months relapse observed 10/50...
<title>Abstract</title> A real-life study on CPX-351 and the standard arm (‘7 + 3’) of registrative trial in adults with secondary Acute Myeloid Leukemia were compared by an unanchored Matching-adjusted indirect comparison (MAIC), order to evaluate efficacy toxicity CPX-351. Results this are important confirm role significantly improving survival remission rates ‘7 3’ a good safety profile AML patients high-risk features, target group traditionally very poor prognosis. Moreover, pilot...
Background: Wilms' tumor gene 1 (WT1) is a critical player in acute myeloid leukemia (AML), often serving as biomarker for measurable residual disease (MRD). The WT1 overexpressed the majority of AML cases at diagnosis, with apparently no correlation prognosis, and meantime, its role patients low-level expression still undefined. This study investigates mutational landscape clinical outcomes low diagnosis. Methods: We analyzed 34 (WT1/ABL1 < 250) diagnosed treated from 2013 to 2017 three...
Antibody-targeted chemotherapy is a promising approach in patients with hematological malignancies. In particular, gemtuzumab ozogamicin (GO, formerly CMA-676), an anti-CD33 antibody linked to calicheamicin, has been approved for the treatment of elderly acute myeloid leukemia (AML) relapse. Nevertheless, no data are until now available concerning possible efficacy GO sarcomas (MS). We treated 24 AML patients, 5 cases presenting skin or bones. The overall complete response rate was 21%....
The molecular basis of advanced systemic mastocytosis (SM) is not fully understood and despite novel therapies the prognosis remains dismal. Exome sequencing an index-patient with mast cell leukemia (MCL) uncovered biallelic loss-of-function mutations in SETD2 histone methyltransferase gene. Copy-neutral loss-of-heterozygosity at 3p21.3 (where maps) was subsequently found SM patients prompted us to undertake in-depth analysis copy number, mutation status, transcript expression methylation...
Despite widespread use of decitabine to treat acute myeloid leukaemia (AML), data on its effectiveness and safety in the real-world setting are scanty. Thus, analyze performance clinical practice, we pooled together patient-level three multicentric observational studies conducted since 2013 throughout Italy, including 306 elderly AML patients (median age 75 years), unfit for intensive chemotherapy, treated with first-line therapy at registered schedule 20 mg/m2 /iv daily 5 days every 4...
Fludarabine plus cytarabine (Ara-C) and idarubicin (FLAI) is an effective well-tolerated induction regimen for the treatment of acute myeloid leukaemia (AML). This phase III trial compared efficacy toxicity FLAI versus Ara-C etoposide (ICE) in 112 newly diagnosed AML patients <60 years. Fifty-seven received FLAI, as first induction-remission course, 55 ICE. Post-induction consisted high-dose (HDAC). After HDAC, complete remission (CR) a second consolidation course (mitoxantrone, etoposide,...
Doxorubicin (Dox) is one of the most commonly used anthracyclines for treatment solid and hematological tumors such as B-/T cell acute lymphoblastic leukemia (ALL). Dox compromises topoisomerase II enzyme functionality, thus inducing structural damages during DNA replication causes direct intercalating into double helix. Eukaryotic cells respond to by activating ATM-CHK2 and/or ATR-CHK1 pathway, whose function regulate cycle progression, promote damage repair, control apoptosis. We evaluated...